Allergan: Botox to the bladder is nothing to frown at
This article was originally published in Scrip
Executive Summary
Botox is the first drug to be approved for the treatment of neurogenic bladder in patients who are intolerant to anticholinergic drugs. Lack of dry mouth and constipation side effects with Botox are big advantages, yet the need to be administered by a specialist will limit uptake. Nevertheless, Allergan’s commercial resources will help drive sales in this niche population.
You may also be interested in...
Novartis’s failure in osteoporosis could be bad break for Tarsa
Novartis’s SMC021 failed to meet main fracture reduction endpoints in osteoporosis Phase III trial. While the result is arguably unsurprising for a calcitonin candidate, it is a setback for other companies such as Tarsa Therapeutics aiming to stimulate growth of the class. Tarsa may now struggle to secure a partner willing to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue development of SMC021 and focus on more attractive targets for osteoporosis treatment.
FDA setback the last straw for Merck's women's health portfolio?
Merck admission that it has received a complete response letter from the FDA for its novel contraceptive Nomac E2 (nomegestrol acetate/17 beta estradiol) may spell the end for more than just this product, analysts at Datamonitor say.
Lilly poised for windfall following FDA approval of Cialis for BPH indications
Eli Lilly is poised to benefit from a windfall after FDA granted marketing authorisation for once daily Cialis (tadalafil) to treat men with BPH symptoms alone or with both BPH and erectile dysfunction. This is the first drug to offer this convenient option to patients. These new indications will provide Eli Lilly with an estimated additional $150m in annual sales for Cialis in the US.